Skip to Main Content

And so, another working week will soon draw to a close. This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest, actually. We plan to catch up on some reading, spend time with Mrs. Pharmalot, and tidy up around the castle. And what about you? You could attend an inaugural ball or, perhaps, lend your voice to a protest. The times they are a changing, as they say. Or you might tune things out and take a peaceful drive somewhere quiet. Well, whatever you do, have a grand time, but be safe. Enjoy and see you soon…

In another setback for Bristol-Myers Squibb and its efforts to dominate the market for cancer treatments, the drug maker disclosed it will not pursue accelerated approval for combining its Opdivo and Yervoy medicines to treat first-line lung cancer. The company disappointed investors last year when Opdivo failed to show progression-free survival in patients with newly diagnosed non-small cell lung cancer. Bristol shares fell 8 percent in pre-market trading.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • Guess that BMS may have to give those gauzy “A CHANCE TO LIVE LONGER” commercials that pop up every 5 minutes a rest, along with the other q 5 minute Pfizer ads warning guys that popping a Viagra will cause their moles to become cancerous.

Comments are closed.